Amicus Therapeutics Inc (NASDAQ:FOLD) Beats Q2 2025 Earnings and Revenue Estimates, Shares Rise in Pre-Market Trading

Amicus Therapeutics Inc (NASDAQ:FOLD) reported second-quarter 2025 financial results, delivering revenue and earnings per share (EPS) that exceeded analyst expectations. The company's performance, coupled with steady growth in its key therapies, has triggered a positive market reaction in pre-market trading, with shares up approximately 2.77%.

Key Financial Highlights

• Revenue: Reported Q2 revenue of $154.7 million, an 18% increase year-over-year at constant exchange rates (CER), surpassing the consensus estimate of $150.0 million.
• Earnings Per Share (EPS): Posted $0.01 per share, a significant beat compared to the estimated loss of $0.12 per share.
• Product Performance:
  • Galafold®, the company’s Fabry disease treatment, generated $128.9 million, up 12% at CER.
  • Pombiliti® + Opfolda®, the Pompe disease therapy, contributed $25.8 million, surging 58% year-over-year.

Market Reaction

The strong earnings beat has driven investor optimism, reflected in the pre-market uptick. Over the past month, FOLD shares have gained nearly 5%, though they remain slightly negative (-2.85%) over the past week. The positive EPS surprise—turning a projected loss into a profit—likely contributed to the bullish sentiment.

Forward-Looking Estimates vs. Performance

Analysts forecast full-year 2025 revenue at $633.3 million, with Q3 sales expected to reach $167.6 million and EPS of $0.02. While the company did not provide explicit guidance in the press release, the Q2 outperformance suggests potential upside to these estimates if current growth trends persist.

Press Release Summary

The earnings update emphasized:

• Continued commercial execution, with both Galafold and Pombiliti + Opfolda showing robust demand.
• Progress in clinical studies for pediatric Pompe disease patients.
• No major operational disruptions or pipeline setbacks reported.

For a deeper dive into Amicus Therapeutics’ earnings history and future estimates, review the full earnings and estimates breakdown.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult a financial advisor before making decisions.